Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Taghi Kimyai-Asadi

Neurology Washington, DC Medical Doctor

NPI 1154328615 CMS profile 142513

1328 Southern Ave Se, Suite 317, Washington, DC 20032

Open in the dashboard

General payments

$2,380

132 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Taghi Kimyai-Asadi of Washington, DC is reported in the CMS Open Payments database as having received $2,380 across 132 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33 1
2024 General $210 10
2023 General $132 7
2022 General $384 18
2021 General $493 29
2020 General $507 30
2019 General $621 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Taghi Kimyai-Asadi
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Taghi Kimyai-Asadi were reported at $33. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Taghi Kimyai-Asadi Neurology median Middle half National median
2019 $621 $474 $118–$2,177 $163
2020 $507 $367 $82–$2,309 $114
2021 $493 $438 $104–$2,547 $132
2022 $384 $442 $103–$2,388 $149
2023 $132 $464 $119–$2,312 $160
2024 $210 $468 $119–$2,323 $164
2025 $33 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sunovion Pharmaceuticals Inc. $698 37 payments
  2. Biogen, Inc. $280 18 payments
  3. Novartis Pharmaceuticals Corporation $246 14 payments
  4. Eisai Inc. $161 8 payments
  5. AbbVie, Inc. $112 5 payments
  6. Supernus Pharmaceuticals, Inc. $108 6 payments
  7. Teva Pharmaceuticals USA, Inc. $91 6 payments
  8. Lilly USA, LLC $82 4 payments
  9. EMD Serono, Inc. $68 4 payments
  10. Neurelis, Inc. $60 3 payments
  11. Other $474 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,380 132 payments
Products named General payments · program years 2019–2025
  1. APTIOM $684 37 payments
  2. KESIMPTA $233 13 payments
  3. Fycompa $161 8 payments
  4. MAYZENT $147 9 payments
  5. VUMERITY $143 7 payments
  6. AUSTEDO $91 6 payments
  7. QULIPTA $82 3 payments
  8. ADUHELM $70 6 payments
  9. TROKENDI XR $64 3 payments
  10. OXTELLAR XR $62 4 payments
  11. Other $889 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

1,627

Median for Neurology: 833

Drug cost

$237,047

Median for Neurology: $202,670

Branded share of claims

10%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rebif Interferon Beta-1a/Albumin Brand 13 $137,402
Aptiom Eslicarbazepine Acetate Brand 26 $43,326
Viibryd Vilazodone Hcl Brand 24 $8,399
Levetiracetam Generic 235 $7,669
Gabapentin Generic 282 $5,161
Vilazodone Hcl Generic 22 $4,675
Memantine Hcl Er Memantine Hcl Brand 37 $4,153
Lacosamide Generic 11 $3,646
Oxcarbazepine Generic 47 $3,403
Donepezil Hcl Generic 101 $2,342

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$51,642

Medicare's payments for the services billed

Medicare patients

149

Average age 71

Services billed

482

98 women, 51 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 52%
Chronic kidney disease 32%
Depression 31%
Ischemic heart disease 27%
Alzheimer's or dementia 26%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $38
$38 — —
APTIOM
  • Sumitomo Pharma America, Inc. $33
$33 26 —
VALTOCO
  • Neurelis, Inc. $26
$26 — —
AMYVID
  • Lilly USA, LLC $25
$25 — —
FYCOMPA
  • CATALYST PHARMACEUTICALS, INC. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

132 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record